Valeant Pharmaceuticals is relying on outside PR support in its $8.7B acquisition of Bausch + Lomb.Valeant Relies on PR in $8.7B Bausch+Lomb Deal
Fri., May 31, 2013
By Greg Hazley
Valeant Pharmaceuticals is relying on outside PR support in its $8.7B acquisition of Bausch + Lomb.Read Full Story in Subscriber Area
Category: M&A
More M&A posts from O'Dwyer's:
| • | Spectrum Acquires ContinuumThu., Feb. 8, 2024
|
Spectrum Science acquires clinical trial recruitment and engagement solutions provider Continuum Clinical.| • | When it's Time to Sell Your PR AgencyFri., Jan. 19, 2024
|
How PR agency owners can navigate the M&A process in a way that yields a rewarding experience for both owners and the teams they leave behind.| • | Selling Your PR Agency? Your Employees Might Thank YouFri., Oct. 13, 2023
|
Ten potential ways an agency sale can positively benefit team members and employees.| • | Kekst Works Palladium's NAP AcquisitionThu., Jul. 6, 2023
|
Kekst CNC reps Palladium Equity Partners and its joint venture affiliate, Palladium Heritage, on the acquisition of National Auto Parts, USA;, NAP San Diego; and National Auto Parts-Oakland to form Collision Auto Parts, a platform serving customers in the automotive aftermarket collision repair sector.| • | ICR Acquires Bullfrog + BaumTue., Jun. 6, 2023
|
ICR has acquired Bullfrog + Baum, the 23-year-old PR shop focused on the hospitality, lifestyle, travel and consumer marketing sectors.
Have a comment? Send it to 
No comments have been submitted for this story yet.